Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.63 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | BACE1 | P56817 | 5/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2028934 | 0.90 | TP53 (0.53) | CYP1A2CYP3A4CYP2C19CYP2C9CLK4 | |
| SCHEMBL2027331 | 0.89 | CCNT1 (0.64) | CYP1A2CYP3A4CYP2C19CYP2C9CLK4 | |
| SCHEMBL2024011 | 0.88 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2C19CYP2C9CLK4 | |
| SCHEMBL12984174 | 0.88 | CCNT1 (0.60) | CYP1A2CYP3A4CYP2C19CYP2C9CLK4 | |
| SCHEMBL2031155 | 0.87 | CCNT1 (0.54) | CYP1A2CYP3A4CYP2C19CYP2C9CLK4 | |
| SCHEMBL2023549 | 0.87 | MAPT (0.53) | CYP1A2CYP3A4CYP2C19CYP2C9CLK4 | |
| SCHEMBL2025425 | 0.86 | CYP1A2 (0.61) | CYP1A2CYP3A4CYP2C19CYP2C9CLK4 | |
| SCHEMBL2027949 | 0.85 | ABL1 (0.48) | CYP1A2CYP3A4CYP2C19CYP2C9CLK4 | |
| SCHEMBL2026511 | 0.85 | CDK9 (0.54) | CYP1A2CYP3A4CYP2C19CYP2C9CLK4 | |
| SCHEMBL2031485 | 0.85 | CCNT1 (0.54) | CYP1A2CYP3A4CYP2C19CYP2C9CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516405-B1 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY | VIROSTATICS S R L (IT) | 2015-09-30 | — | — | EP | disclosed |
| US-9040529-B2 | 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2015-05-26 | — | — | US | disclosed |
| EP-2516405-A1 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY | Vichem Chemie Kutató KFT (HU) | 2012-10-31 | — | — | EP | disclosed |
| US-20120258968-A1 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY | VIROSTATICS S.R.L. (IT) | 2012-10-11 | — | — | US | disclosed |
| WO-2011077171-A1 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258968-A1 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY | CDK9, CDK19, CDKL3 | CYP1A2 3521/4885CYP3A4 2541/4885CYP2C19 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.